Halozyme Therapeutics (HALO) PT Raised to $55 at JPMorgan
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.46 -1.69%
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
JPMorgan analyst Jessica Fye raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $55.00 (from $49.00) while maintaining a Overweight rating.
You May Also Be Interested In
- JPMorgan Upgrades STO Express Co Ltd (002468:CH) to Neutral
- RBC Capital Downgrades Range Resources (RRC) to Sector Perform
- Canaccord Genuity Downgrades Antofagasta Plc. (ANTO:LN) (ANFGF) to Hold
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
